Optimal Strategies for Managing Adverse Events with CAR-T Therapy in Multiple Myeloma : Episode 5

Strategies to Manage or Mitigate CRS

June 19, 2024

By Beth Faiman, PhD, CNP
Louis Williams, MD

Opinion

Video

Experts on multiple myeloma provide clinical insights on strategies to manage or mitigate CRS, highlighting premedications, the role of bridging therapy, and potential treatment strategies.

EP: 1.Unique Challenges in Managing Adverse Events Associated with CAR T-Cell Therapy

EP: 2.Navigating CAR T-Cell Therapy in Multiple Myeloma: A Collaborative, Patient-Centered Approach

EP: 3.Patient Profile 1: Managing CRS Following CAR T-Cell Therapy

EP: 4.Underlying Mechanisms and Signs of CRS

Now Viewing

EP: 5.Strategies to Manage or Mitigate CRS

EP: 6.Patient Profile 2: Managing ICANS Following CAR T-Cell Therapy

EP: 7.Clinical Practices for Treating ICANS Following CAR T-Cell Therapy

EP: 8.The Importance of Multidisciplinary Collaboration in CRS Management

EP: 9.Supportive Care Strategies for CAR T-Cell Therapy Recipients

EP: 10.Managing Cytopenias and HLH/MAS Following CAR T-Cell Therapy

EP: 11.Unmet Needs and Future Perspectives for CAR T-Cell Therapy in R/R MM

Video content above is prompted by the following question(s):

What are some strategies you can use to manage or mitigate cytokine release syndrome (CRS) in patients receiving cilta-cel therapy?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!